Diadem Biotherapeutics
Diadem Biotherapeutics is a biotechnology company focused on developing first- and best-in-class therapeutics by engineering extracellular vesicles to modulate immune responses. Their mission is to innovate beyond existing solutions to address unmet medical needs, leveraging expertise in immunology, bioengineering, and drug development. The company’s proprietary DECOSTAR™ platform enables precise costimulatory activation or repression of immune cells, targeting a range of diseases including cancer and autoimmunity.
Industries
Nr. of Employees
small (1-50)
Diadem Biotherapeutics
BioLabs at The Lundquist Institute, 1124 W Carson St., MRL Building, 3rd FL, Torrance, CA 90502
Patents
Products
Engineered extracellular vesicle platform for immune modulation
A platform that programs extracellular vesicles to present signaling molecules on their surface to activate or repress costimulatory and checkpoint receptors for therapeutic applications across autoimmune disease and cancer.
Engineered extracellular vesicle platform for immune modulation
A platform that programs extracellular vesicles to present signaling molecules on their surface to activate or repress costimulatory and checkpoint receptors for therapeutic applications across autoimmune disease and cancer.
Expertise Areas
- Extracellular vesicle therapeutics
- Bioprocessing and manufacturing scale-up
- Immuno-oncology and immune receptor modulation
- Protein engineering and gene therapy development
Key Technologies
- Engineered extracellular vesicles (EVs)
- Cell line engineering for bioproduction
- Multi-omics (transcriptomics, proteomics, metabolomics)
- Protein engineering
Key People
Scientist
Scientist
News & Updates
Received the first Amgen Golden Ticket Award at BioLabs LA.
Secured $2.1 million in investment led by various VCs and Family & Friends.
Successfully completed the Creative Destruction Lab startup mentorship program.
Participated in IndieBio's biotechnology accelerator program.
Selected to pitch at the 2019 QB3 Biotech/Biopharma Pitch Summit.
Diadem Biotherapeutics was selected as the winner and recipient of the first Amgen Golden Ticket Award at BioLabs LA.
Received the first Amgen Golden Ticket Award at BioLabs LA.
Secured $2.1 million in investment led by various VCs and Family & Friends.
Successfully completed the Creative Destruction Lab startup mentorship program.
Participated in IndieBio's biotechnology accelerator program.
Selected to pitch at the 2019 QB3 Biotech/Biopharma Pitch Summit.
Diadem Biotherapeutics was selected as the winner and recipient of the first Amgen Golden Ticket Award at BioLabs LA.